ReviewMolecular biology reports2026
The Dual Roles of TIMP-1 in Cancer: From Protease Inhibition to Cytokine Signaling.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
Tissue inhibitor of metalloproteinase-1 (TIMP-1) has emerged as a significant focus in cancer research due to its dual functionality as both an inhibitor of matrix metalloproteinases and a multifunctional cytokine. Recent studies underscore the pivotal role of TIMP-1 in extracellular matrix remodeling, a process essential for tumor progression and metastasis. Moreover, TIMP-1 performs a variety of functions within the tumor microenvironment that extend beyond its traditional protease-inhibitory role, highlighting its importance in modulating cellular processes such as proliferation, apoptosis, and immune responses. Additionally, TIMP-1 has garnered increasing attention as a prognostic biomarker and a potential therapeutic target in oncology. This review systematically compiles recent advancements in the understanding of TIMP-1's dual functions in cancer, elucidates its mechanistic roles as both a metalloproteinase inhibitor and a cytokine-like factor, and integrates its emerging significance as a biomarker and therapeutic target across diverse cancer types. By synthesizing recent findings, this study seeks to provide novel insights into the translational potential of TIMP-1 in cancer treatment, while examining its prospective implications for therapeutic strategies and clinical interventions.
Indexed as
Identifiers
41854852What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.